Jazz Pharmaceuticals (JAZZ) PT Raised to $175 at Deutsche Bank
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $240.74 -1.27%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Deutsche Bank raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $175.00 (from $174.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS says this pharma name offers a robust case for stock outperformance
- Envista Holdings Corp. (NVST) PT Lowered to $27 at UBS, Neutral Rating Maintained
- Sumitomo Metal Mining Co Ltd (5713:JP) PT Raised to JPY9,900 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
